Founded in 2013, INOTREM is a French biopharmaceutical company specialized in the development of innovative therapeutic approaches based on its proprietary TREM-1 platform. INOTREM is focused on the control of immune reactions in acute inflammatory diseases.

The scientific founders of Inotrem identified the key role of the TREM-1 amplification loop in the excessive innate immune reaction in acute inflammatory processes in the critical care setting. INOTREM discovered and developed a new therapeutic modality in the form of a peptide and a new concept of immunomodulation achieved by the inhibition of the TREM-1 amplification loop.

The INOTREM team combines a unique long-time experience in drug development and renown research in inflammatory diseases in critical care. Combining the development of a TREM-1 inhibitor-based therapy with innovative clinical development and a new personalized medicine approach puts the Company at the cutting edge of therapies to manage excessive innate inflammation.



Senior executive with broad and deep experience in R&D in the pharmaceutical industry
  • Head of Pharma Research and Early Development at Roche (2010 to 2012)
  • Head of Development and Chief Medical Officer at Roche (2007 to 2010)
  • Non-Executive Director Enyo, Lyon.


Senior executive with international experience in finance and operational functions.
  • CFO of Genticel, a listed French biotech (2007 – 2017)
  • Sales Director , Oncology Cephalon Pharma France (2006 – 2007)
  • Controlling and Finance Director functions at Elan & Zeneus Pharma UK (2001 – 2005).


PhD in immunology and a post-doctoral fellowship at the University of Lorraine, France.
  • MBA HEC Led the development of TREM-1 inhibitor drug candidates (4 patents, several publications) (2007-2013)
  • Creation of INOTREM (2013)


PhD in Immunology and Tumor Biology at the Karolinska Institute in Stockholm.
  • Director of Translational Research at the Oncology R&D Unit, Servier International Research Institute
  • Director Translational Medicine, LFB biotechnologies, a French biopharmaceutical laboratory on immunology, hemostasis and intensive care therapeutic areas.


CHAIRPERSON: Thierry HERCEND, Edmond de Rothschild Investment Partners

A medical doctor with a PhD in immunology, Thierry has acquired more than 30 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. Since 2006, Thierry has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Thierry was Vice President in charge of the therapeutic oncology sector for Aventis. From 1998 to 2002, Thierry was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of Therapeutic Immunology and then Scientific Director of the Health Division. Before joining the industrial sector, Thierry was a department head, responsible for the Immuno-Hematology laboratory at Gustave Roussy Villejuif Institute, France, and director of the INSERM U333 unit dedicated to the immunology of tumors and professor of immunology at Université de Médecine-Paris XI, France. Thierry is the author of more than 120 publications in oncology, autoimmune diseases and transplantation.

Jean-Jacques GARAUD, Chief Executive Officer INOTREM S.A.

Dr Jean-Jacques Garaud is a medical doctor with over 25 years of experience in pharmaceutical research and development in the United States and Europe. He began his industry career as a Clinical Research Physician, and went on to hold positions of increasing seniority at Rhone-Poulenc Rorer and Schering-Plough, where he became Executive Vice President of Worldwide Clinical Research. He subsequently held a number of positions within Novartis, including Global Head of Clinical Research and Development. On moving to F Hoffmann-La Roche, Jean-Jacques became Global Head of Pharmaceutical Development and Chief Medical Officer, and most recently led Roche Pharma Research and Early Development. During his career he led the development and subsequent approval of many pharmaceutical products. Prior to his time in the pharmaceutical industry, Jean-Jacques practiced medicine at the Claude Bernard Hospital in Paris (Infectious Diseases and Intensive Care Medicine) after gaining his medical degree at the University of Paris.

Gilles NOBÉCOURT, Edmond de Rothschild Investment Partners

Gilles has been a Partner at Edmond de Rothschild Investment Partners since 2002. Prior to this he worked as a consultant dedicated to pharmaceutical and biotechnology companies for Russell Reynolds & Associates. In 1988, Gilles started at Rhône-Poulenc Group as Vice President, Public Affairs. In 1992, he was appointed Vice President, assistant to the Chairman and CEO of Rhône-Poulenc Rorer, the pharmaceutical affiliate of Rhône-Poulenc. He then became a founding member of RPR Gencell, the biotechnology division of Rhône-Poulenc Rorer. Initially General Manager for Europe, he subsequently became deputy General Manager of the Division based in San Francisco until 1999. He was then appointed General Manager of a commercial subsidiary in Mexico City. Before he started at Rhône-Poulenc, he was a Field Officer for the United Nations High Commissioner for Refugees in Africa and Central America, advisor to the French Prime Minister (1984-1986), advisor to the French Minister for Industry and Research (1983), Chief of Staff to the President of Languedoc Roussillon Regional Council (1982) and Social Advisor in the French Senate (1981-1982). Gilles graduated from the Paris Institute for Political Sciences (‘Sciences Po Paris’) in 1980, holds also a Master degree in applied economics and a certificate from the Stanford Global School of Business.

Graziano SEGHEZZI, Sofinnova Partners

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seed invested and is on the Board of Mission Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).

François THOMAS, Inserm Transfert Initiative

Dr. François Thomas is President of Inserm Transfert Initiative (ITI). He is a medical oncologist and a former assistant professor at the Gustave Roussy Institute. He also holds an MBA from MIT (Boston). François Thomas was successively vice president (VP) for clinical development of Ipsen, managing partner of Bioserve Ltd, VP in charge of pharmacogenomic programs and licensing at Genset, partner in the venture capital firm Atlas Venture, in charge of healthcare banking activities at Bryan Garnier, and president of Cytheris. His professional activity over the last 15 years has been dedicated to the creation and development of biotech companies in Europe.

Thomas MOELLER, BioMedInvest

Mr. Moeller has strong experience in the valuation of early stage and start-up companies in the life science sector and large multinational organizations. Until 2003 he worked as Chief Financial Officer at NMT New Medical Technologies focusing on private equity investments in biopharmaceutical and biotechnological companies. He was financial advisor in several private biotechnology investments of NMT and responsible for financial aspects of the portfolio companies of NMT. Before joining NMT, he worked from 1992-2001 as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States gaining vast experience in early stage and start-up companies in the life science sector as well as large multinational organizations. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.

Marc DERIVE, Chief Scientific Officer INOTREM S.A.

Dr. Marc Derive, PhD, is the co-founder and actual Chief Scientific Officer of INOTREM. After successfully completing a Masters degree of Business and Engineering, he joined the team of Professor Sebastien Gibot in 2007 to complete a PhD in immunology and a post-doctoral fellowship at the University of Lorraine, France. He worked on the role of TREM-1 in the pathogenesis of septic shock and other acute and chronic inflammatory conditions. Marc Derive completed his scientific background with education in business and administration at HEC business school (Paris). His work has led to the development of TREM-1 inhibitor drug candidates, 4 patents, several publications and the creation of INOTREM in 2013.

Scientific Advisory Board


Professor Sebastien GIBOT is co-founder of INOTREM. Pr Sebastien Gibot is Professor of Intensive Care Medicine at Hopital Central, Nancy, France. He managed Dr Marc Derive’s thesis and thus co-developed anti-sepsis compounds. Pr Sebastien Gibot has over 15 years’ experience of fundamental and clinical research in the field of immunotherapy of sepsis. He authored 67 peer reviewed papers and has 4 patents in the field. Pr Sebastien Gibot is known and recognized as the international specialist of TREM-1 and he is largely implicated in the scientific and development activities of INOTREM Company.


Founder of Vonderscher&Co GmbH
Senior executive with a broad R&D experience in the pharmaceutical industry
Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
Board member of Inatherys and ObsEva and SAB member of Inotrem

Jacques MIZRAHI, PhD.

Jacques Mizrahi Ph.D, has been a senior executive with 20 plus years of big pharma global leadership experience in Discovery and Development (GSK, E. Lilly, Roche). Jacques has led several successful drug development programs in vascular, cardiovascular and metabolic diseases. At Roche, as Global Therapy Area Head, he led the discovery and development of several new molecular entities for Acute Coronary Syndromes, Diabetes and Diabetes complications and has developed significant expertise in bridging the discovery of new target pathways and the clinics via translational medicine projects. Jacques obtained his Ph.D in Pharmacology from the University of Sherbrooke, Canada and then held postdoctoral fellowships at each of Sherbrooke Medical School and at INSERM Paris where he focused on protein biochemistry. Jacques has over 100 peer reviewed publications. Additionally, he contributes to peer journal Editorial Boards and sits on Advisory Boards of academic, biotech and venture capital organizations.


Pr Denis Hochstrasser is Vice-Rector/ Vice President of Geneva University, in charge of the research and computer sciences sectors. He is also chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital. He is as a Board certified physician in internal medicine & in clinical chemistry. At the academic level, he is full Professor both to Geneva's Department of Human Protein Sciences, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. He was one of the founders of the Swiss Institute for Bioinformatics, of the Swiss Centre for Applied Human Toxicology and also of Biobank Swiss Foundation. He is a scientific founder of Geneva Proteomics Inc, Geneva Bioinformatics SA and of Eclosion SA. He is a board member of the CTI certification board for the Swiss Government and of Viollier laboratories. His research focus on the discovery of clinical biomarkers in brain, pancreas and kidney diseases, in human toxicology and the development of proteomic & clinical chemistry related technologies such as clinical mass spectrometry.

Pierre LAUNAY, PhD.

Co-founder and CSO Inatherys. Doctor in Immunology, Inserm research director and team “Avenir” director of the U699 unit. Doctoral student at Necker hospital, Pierre has more than 17 years of experience in basic research on monoclonal antibodies and their therapeutic implications and has published some of his work in scientific journals such as Cell, Nature et Science. He coordinated several projects on inflammation (NIH Grant R01, ANR-Genopath) and cancer (ARC) as well as a research program in allergology (Foundation for medical research). Former Instructor at Harvard Medical School in Boston for 6 years, he characterized new therapeutic targets (ion channels) in inflammation. He was also a scientific consultant for 4 years for Synta Pharmaceuticals biotechnology company located in Lexington. As such, he took part in the creation, in 2001, of a research department within the company on ion channels’ agonists for applications in inflammation. He undertook the Challenge+ training program of French management and business school (HEC).

Albert HECK, PhD.

The research group of Albert Heck at Utrecht University has a large track record in quantitative proteomics and the analysis of protein post-translational modifications. For example, he introduced TiO2 as enrichment material for the targeted analysis of phosphopeptides, introduced the use of a protease named LysN that in conjunction with ETD provides unique sequence ladders that are straightforward to interpret and has an extensive track record in developing quantitative proteomics strategies, introducing metabolic stable isotope labeling in multicellular organisms and stable isotope labeling by using chemical approaches. The Heck group is also leading in macromolecular or native mass spectrometry, which enables the analysis of intact proteins and protein assemblies by mass spectrometry. The group develops mass spectrometers dedicated for this work and applies these technologies to study the structure and dynamics of for instance transcription complexes, such as RNA polymerase, and virus assembly. The infrastructure and technology available at the Heck group includes state-of-the art proteomics equipment, with over 20 mass spectrometers and expert proteomics technology to study a variety of post-translational modifications, quantitate changes in protein interaction networks and the detailed characterization of intact protein complexes.

Clinical development advisory board


Professor Sebastien GIBOT is co-founder of INOTREM. Pr Sebastien Gibot is Professor of Intensive Care Medicine at Hopital Central, Nancy, France. He managed Dr Marc Derive’s thesis and thus co-developed anti-sepsis compounds. Pr Sebastien Gibot has over 15 years’ experience of fundamental and clinical research in the field of immunotherapy of sepsis. He authored 67 peer reviewed papers and has 4 patents in the field. Pr Sebastien Gibot is known and recognized as the international specialist of TREM-1 and he is largely implicated in the scientific and development activities of INOTREM Company.

Pierre-François LATERRE, M.D.

Pierre-François Laterre, MD, is professor of medicine and the Head of the medical-surgical intensive care unit at Saint Luc University Hospital at the Université Catholique de Louvain, Brussels, Belgium. In 1990 he graduated in Internal Medicine and in 1991 in Intensive Care Medicine at Saint Luc University Hospital, Université Catholique de Louvain, Brussels: University Hospital Practionner at CHRU of Nancy (France) and Research Fellow at the Johns Hopkins Hospital (Baltimore, USA) in 93. He has dedicated most of his professional and scientific activity to the diagnosis, investigation and treatment of sepsis and especially its interaction with the coagulation cascade, inflammation and host response. Liver Failure and Transplantation, ARDS, Acute Renal Failure, Infectious Diseases are his topics of interest. He has a large experience in multicenter, randomized, double blind studies and he is Director of the Clinical Coordinating Center of the Compass trial (PAF inhibition in sepsis), CAPTIVATE, ACCESS, ART 123 trials. He is member of the European Society of Intensive Care Medicine, Society of CCM and of several advisory boards. He is currently president of the French Society of Critical Care.


Tom van der Poll is Professor of Medicine in the Academic Medical Center (AMC), University of Amsterdam, the Netherlands. He is Head of the Center of Experimental and Molecular Medicine and Chair of the Division of Infectious Diseases in this institution. Van der Poll is board certified in Internal Medicine and Infectious Diseases. His training included a postdoctoral research fellowship in Cornell University Medical College in New York (1993-1995). Van der Poll is a former Fellow of the Royal Dutch Academy of Arts and Sciences (1995-2000). Van der Poll is council member of the Global Sepsis Alliance (GSA, www.globalsepsisalliance.org) and immediate past Chair of the International Sepsis Forum (ISF, www.internationalsepsisforum.org), an organization headed by a council of international experts and opinion leaders that focuses on improving the management of sepsis and septic shock. He is a member of the “International Task Force Committee for Sepsis Definitions” (installed by ESICM & SCCM) and the “Surviving Sepsis Guidelines Committee”. Van der Poll’s research focuses on the innate immune and procoagulant response during sepsis.


Dr. François is specialist in Intensive Care medicine and Anaesthesiology at the University Hospital of Limoges, France. He works in a 22 bed medical/surgical ICU and is the head of the Limoges Clinical Investigation Center (Inserm CIC-P 1435) of which main expertise is Infectious Diseases in critically ill patients. He has been national coordinator for numerous emergency trials especially in Sepsis, VAP and VAP prevention, and has participated in several advisory boards for Sepsis and VAP multinational trials, independent Clinical Evaluation Committees and Adjudication Committees. He is author of many publications in Infectious Disease in the ICU especially about Sepsis and VAP and is also reviewer for several medical journals in the ICU field. He has an expertise in the practical bedside organization of clinical research in the ICU. He has also an interest in more translational studies and research about the immunological disorders of Sepsis evaluated by flow cytometry and its potential treatments. He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and is now co-leading the French TRIGGERSEP research network (F-CRIN certification within ECRIN) which integrate all research activities in Sepsis from basic science to clinical trials. Since 2012, he is coordinating the COMBACTE consortium within the IMI framework.

Philippe JACQMIN, PhD.

Philippe Jacqmin is a Director and one of the founders of Exprimo. He was born in 1956 in Belgium and obtained his Pharm.D. degree from the University of Louvain in 1979 and his Ph.D. degree in Pharmaceutical Sciences from the same University in 1984. From 1984 to 1988 he was successively assistant and first assistant at the Department of Pharmacology at the University of Louvain and was responsible for the Therapeutic Drug Monitoring Unit at the St. Luc University Clinics. From 1988 to 1993 Philippe worked as Group Leader Pharmacokinetics and Drug Metabolism at the Searle European Development Centre in Belgium. From 1993 to 2000 he held several positions within the Departments of Non-clinical and Clinical Pharmacokinetics at the Janssen Research Foundation (a Johnson & Johnson company) in Belgium where he was one the initiators of the Exploratory Development group. From 2000 to 2002, he worked for Pharsight Corporation as Consultant within the European Scientific Affairs Group. Philippe has 15 years of preclinical as well as clinical drug development experience. He is author or co-author of more than 35 original research papers and approximately 60 scientific abstracts and contributed to six textbooks dealing with pharmacokinetics and PK/PD modelling. He also contributed to several registration dossiers for new drug applications. Philippe lives in Belgium.


Dr. Francois Vandenhende is the founder and CEO of ClinBAY, a statistical CRO that delivers cost-effective quantitative solutions to pharmaceutical decision makers. Dr. Vandenhende is a clinical statistician, specialized in Bayesian methods and adaptive designs. He provides statistical insight into scientific advisory boards for various biotech companies. He is also managing strategic alliances for ClinBAY with several global pharmaceutical customers. Prior to joining ClinBAY, Francois started his career at Merck for 1 year, then moved to Eli Lilly and Company for 14 years, where he ended as the global head of CNS early phase statistics. He has a Ph.D. degree in statistics from UCL, Belgium.


In February 2014, INOTREM raised a Series A round of €18 million, which was co-led by the leading international life science venture capitalists Edmond de Rothschild Investment Partners and Sofinnova Partners and included Switzerland-based BioMed Partners and the French seed investment firm Inserm Transfert Initiative. The round was among the largest Series A financings worldwide in 2014 and supports the development of INOTREM’s lead product through late stage preclinical and early clinical trials in severe sepsis.

 At a very early stage of its inception, INOTREM received vital support from the Incubateur Lorrain  and the University of Lorraine  in Nancy, Region Lorraine , BPI France  and Inserm Transfert .